Medical - Instruments & Supplies
Compare Stocks
5 / 10Stock Comparison
MMSI vs ISRG vs SYK vs MDT vs ABT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Medical - Devices
Medical - Devices
MMSI vs ISRG vs SYK vs MDT vs ABT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices | Medical - Devices |
| Market Cap | $3.72B | $161.07B | $112.69B | $99.94B | $151.30B |
| Revenue (TTM) | $1.54B | $10.58B | $25.12B | $35.48B | $43.84B |
| Net Income (TTM) | $139M | $2.98B | $3.25B | $4.61B | $13.98B |
| Gross Margin | 48.7% | 66.3% | 63.5% | 61.9% | 54.0% |
| Operating Margin | 12.2% | 30.5% | 22.4% | 17.9% | 17.8% |
| Forward P/E | 15.1x | 43.3x | 19.1x | 13.8x | 15.4x |
| Total Debt | $898M | $303M | $14.86B | $28.52B | $15.28B |
| Cash & Equiv. | $449M | $3.37B | $4.01B | $2.22B | $7.62B |
MMSI vs ISRG vs SYK vs MDT vs ABT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Merit Medical Syste… (MMSI) | 100 | 136.2 | +36.2% |
| Intuitive Surgical,… (ISRG) | 100 | 232.8 | +132.8% |
| Stryker Corporation (SYK) | 100 | 145.8 | +45.8% |
| Medtronic plc (MDT) | 100 | 77.2 | -22.8% |
| Abbott Laboratories (ABT) | 100 | 88.8 | -11.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MMSI vs ISRG vs SYK vs MDT vs ABT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MMSI lags the leaders in this set but could rank higher in a more targeted comparison.
ISRG ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs MMSI's 214.6%
- 20.5% revenue growth vs MDT's 3.6%
Among these 5 stocks, SYK doesn't own a clear edge in any measured category.
MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Beta 0.47, yield 3.6%, current ratio 1.85x
- Lower P/E (13.8x vs 19.1x)
- 3.6% yield, 36-year raise streak, vs ABT's 2.5%, (2 stocks pay no dividend)
ABT is the #2 pick in this set and the best alternative if sleep-well-at-night and valuation efficiency is your priority.
- Lower volatility, beta 0.25, Low D/E 31.9%, current ratio 1.67x
- PEG 0.51 vs MDT's 35.17
- 31.9% margin vs MMSI's 9.0%
- Beta 0.25 vs ISRG's 1.02
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs MDT's 3.6% | |
| Value | Lower P/E (13.8x vs 19.1x) | |
| Quality / Margins | 31.9% margin vs MMSI's 9.0% | |
| Stability / Safety | Beta 0.25 vs ISRG's 1.02 | |
| Dividends | 3.6% yield, 36-year raise streak, vs ABT's 2.5%, (2 stocks pay no dividend) | |
| Momentum (1Y) | -2.8% vs MMSI's -33.8% | |
| Efficiency (ROA) | 175.8% ROA vs MMSI's 5.2%, ROIC 6.0% vs 7.2% |
MMSI vs ISRG vs SYK vs MDT vs ABT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MMSI vs ISRG vs SYK vs MDT vs ABT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
MMSI leads 1 • MDT leads 1 • SYK leads 0 • ABT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ABT is the larger business by revenue, generating $43.8B annually — 28.4x MMSI's $1.5B. ABT is the more profitable business, keeping 31.9% of every revenue dollar as net income compared to MMSI's 9.0%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.5B | $10.6B | $25.1B | $35.5B | $43.8B |
| EBITDAEarnings before interest/tax | $290M | $3.8B | $6.3B | $9.4B | $10.9B |
| Net IncomeAfter-tax profit | $139M | $3.0B | $3.2B | $4.6B | $14.0B |
| Free Cash FlowCash after capex | $274M | $2.8B | $4.3B | $5.4B | $6.9B |
| Gross MarginGross profit ÷ Revenue | +48.7% | +66.3% | +63.5% | +61.9% | +54.0% |
| Operating MarginEBIT ÷ Revenue | +12.2% | +30.5% | +22.4% | +17.9% | +17.8% |
| Net MarginNet income ÷ Revenue | +9.0% | +28.2% | +12.9% | +13.0% | +31.9% |
| FCF MarginFCF ÷ Revenue | +17.8% | +26.8% | +17.1% | +15.2% | +15.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.8% | +23.0% | +11.4% | +8.8% | +6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.8% | +18.8% | +56.0% | -11.9% | 0.0% |
Valuation Metrics
MMSI leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 11.4x trailing earnings, ABT trades at a 80% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), ABT offers better value at 0.38x vs MDT's 35.17x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $3.7B | $161.1B | $112.7B | $99.9B | $151.3B |
| Enterprise ValueMkt cap + debt − cash | $4.2B | $158.0B | $123.5B | $126.2B | $159.0B |
| Trailing P/EPrice ÷ TTM EPS | 29.26x | 57.62x | 35.03x | 21.60x | 11.39x |
| Forward P/EPrice ÷ next-FY EPS est. | 15.05x | 43.35x | 19.06x | 13.80x | 15.40x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.65x | 2.36x | 35.17x | 0.38x |
| EV / EBITDAEnterprise value multiple | 13.06x | 43.62x | 20.31x | 14.32x | 15.83x |
| Price / SalesMarket cap ÷ Revenue | 2.45x | 16.00x | 4.49x | 2.98x | 3.61x |
| Price / BookPrice ÷ Book value/share | 2.38x | 9.17x | 5.02x | 2.08x | 3.18x |
| Price / FCFMarket cap ÷ FCF | 17.24x | 64.67x | 26.31x | 19.28x | 23.82x |
Profitability & Efficiency
ISRG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ABT delivers a 27.3% return on equity — every $100 of shareholder capital generates $27 in annual profit, vs $9 for MMSI. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SYK's 0.66x. On the Piotroski fundamental quality scale (0–9), ABT scores 7/9 vs MDT's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +8.9% | +16.9% | +15.0% | +9.4% | +27.3% |
| ROA (TTM)Return on assets | +5.2% | +14.8% | +6.9% | +175.8% | +16.6% |
| ROICReturn on invested capital | +7.2% | +15.0% | +11.4% | +6.0% | +9.9% |
| ROCEReturn on capital employed | +7.9% | +16.5% | +13.0% | +7.5% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 6 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.57x | 0.02x | 0.66x | 0.59x | 0.32x |
| Net DebtTotal debt minus cash | $450M | -$3.1B | $10.8B | $26.3B | $7.7B |
| Cash & Equiv.Liquid assets | $449M | $3.4B | $4.0B | $2.2B | $7.6B |
| Total DebtShort + long-term debt | $898M | $303M | $14.9B | $28.5B | $15.3B |
| Interest CoverageEBIT ÷ Interest expense | 10.74x | — | 6.72x | 9.08x | 19.22x |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $7,230 for MDT. Over the past 12 months, MDT leads with a -2.8% total return vs MMSI's -33.8%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs MMSI's -9.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -27.9% | -19.3% | -15.2% | -18.1% | -28.9% |
| 1-Year ReturnPast 12 months | -33.8% | -15.4% | -22.5% | -2.8% | -33.2% |
| 3-Year ReturnCumulative with dividends | -26.5% | +49.6% | +5.5% | -4.2% | -15.4% |
| 5-Year ReturnCumulative with dividends | -3.6% | +58.7% | +21.5% | -27.7% | -17.9% |
| 10-Year ReturnCumulative with dividends | +214.6% | +554.2% | +187.1% | +26.5% | +173.7% |
| CAGR (3Y)Annualised 3-year return | -9.8% | +14.4% | +1.8% | -1.4% | -5.4% |
Risk & Volatility
Evenly matched — ISRG and ABT each lead in 1 of 2 comparable metrics.
Risk & Volatility
ABT is the less volatile stock with a 0.25 beta — it tends to amplify market swings less than ISRG's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ISRG currently trades 75.1% from its 52-week high vs MMSI's 62.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 1.00x | 0.52x | 0.42x | 0.22x |
| 52-Week HighHighest price in past year | $100.19 | $603.88 | $404.87 | $106.33 | $139.06 |
| 52-Week LowLowest price in past year | $59.74 | $427.84 | $289.91 | $77.16 | $86.15 |
| % of 52W HighCurrent price vs 52-week peak | +62.2% | +75.1% | +72.7% | +73.3% | +62.6% |
| RSI (14)Momentum oscillator 0–100 | 34.9 | 42.4 | 24.3 | 27.3 | 22.9 |
| Avg Volume (50D)Average daily shares traded | 769K | 1.8M | 2.1M | 7.8M | 10.5M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: MMSI as "Buy", ISRG as "Buy", SYK as "Buy", MDT as "Buy", ABT as "Buy". Consensus price targets imply 52.4% upside for MMSI (target: $95) vs 32.4% for SYK (target: $390). For income investors, MDT offers the higher dividend yield at 3.57% vs SYK's 1.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $95.00 | $622.60 | $389.62 | $109.50 | $128.71 |
| # AnalystsCovering analysts | 14 | 55 | 50 | 49 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.1% | +3.6% | +2.5% |
| Dividend StreakConsecutive years of raises | — | — | 34 | 36 | 11 |
| Dividend / ShareAnnual DPS | — | — | $3.36 | $2.78 | $2.19 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% | 0.0% | +3.2% | +0.9% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MMSI leads in 1 (Valuation Metrics). 1 tied.
MMSI vs ISRG vs SYK vs MDT vs ABT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MMSI or ISRG or SYK or MDT or ABT a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Abbott Laboratories (ABT) offers the better valuation at 11. 4x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate Merit Medical Systems, Inc. (MMSI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MMSI or ISRG or SYK or MDT or ABT?
On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.
4x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 51x versus Medtronic plc's 35. 17x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — MMSI or ISRG or SYK or MDT or ABT?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -27. 7% for Medtronic plc (MDT). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus MDT's +24. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MMSI or ISRG or SYK or MDT or ABT?
By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.
22β versus Intuitive Surgical, Inc. 's 1. 00β — meaning ISRG is approximately 362% more volatile than ABT relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — MMSI or ISRG or SYK or MDT or ABT?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to 4. 9% for Merit Medical Systems, Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MMSI or ISRG or SYK or MDT or ABT?
Abbott Laboratories (ABT) is the more profitable company, earning 31.
9% net margin versus 8. 5% for Merit Medical Systems, Inc. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus 12. 2% for MMSI. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MMSI or ISRG or SYK or MDT or ABT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 51x versus Medtronic plc's 35. 17x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 29. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MMSI: 52. 4% to $95. 00.
08Which pays a better dividend — MMSI or ISRG or SYK or MDT or ABT?
In this comparison, MDT (3.
6% yield), ABT (2. 5% yield), SYK (1. 1% yield) pay a dividend. MMSI, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is MMSI or ISRG or SYK or MDT or ABT better for a retirement portfolio?
For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
22), 2. 5% yield, +166. 6% 10Y return). Both have compounded well over 10 years (ABT: +166. 6%, ISRG: +549. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MMSI and ISRG and SYK and MDT and ABT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MMSI is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock; MDT is a mid-cap income-oriented stock; ABT is a mid-cap deep-value stock. SYK, MDT, ABT pay a dividend while MMSI, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.